{"analyses":[{"ciLowerLimit":"83.6","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"91.0","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Percentage of participants with response","paramValue":"87.7","statisticalMethod":"Two-sided binomial test","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"284"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"324"}],"units":"Participants"}],"description":"CR and PR are defined by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + no increase in size or number of lytic bone lesions; and PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.","groups":[{"description":"Cyclophosphamide + Bortezomib + Dexamethasone for three 21-day cycles","id":"OG000","title":"Cyclophosphamide + Bortezomib + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Per-protocol analysis set: It includes the participants who completed the entire clinical study without major protocol violations.","reportingStatus":"POSTED","timeFrame":"Up to Day 63","title":"Participants With Complete Response (CR) + Partial Response (PR) (Per-protocol Analysis Set)","type":"SECONDARY","unitOfMeasure":"Participants"}